AR109099A1 - Procedimiento de análisis de glicosaminoglicanos, heparinas y sus derivados por resonancia magnética nuclear - Google Patents

Procedimiento de análisis de glicosaminoglicanos, heparinas y sus derivados por resonancia magnética nuclear

Info

Publication number
AR109099A1
AR109099A1 ARP170102020A ARP170102020A AR109099A1 AR 109099 A1 AR109099 A1 AR 109099A1 AR P170102020 A ARP170102020 A AR P170102020A AR P170102020 A ARP170102020 A AR P170102020A AR 109099 A1 AR109099 A1 AR 109099A1
Authority
AR
Argentina
Prior art keywords
derivatives
procedure
magnetic resonance
nuclear magnetic
analysis
Prior art date
Application number
ARP170102020A
Other languages
English (en)
Original Assignee
Farm Rovi Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farm Rovi Lab Sa filed Critical Farm Rovi Lab Sa
Publication of AR109099A1 publication Critical patent/AR109099A1/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N24/00Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects
    • G01N24/08Investigating or analyzing materials by the use of nuclear magnetic resonance, electron paramagnetic resonance or other spin effects by using nuclear magnetic resonance
    • G01N24/087Structure determination of a chemical compound, e.g. of a biomolecule such as a protein
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46NMR spectroscopy
    • G01R33/4625Processing of acquired signals, e.g. elimination of phase errors, baseline fitting, chemometric analysis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01RMEASURING ELECTRIC VARIABLES; MEASURING MAGNETIC VARIABLES
    • G01R33/00Arrangements or instruments for measuring magnetic variables
    • G01R33/20Arrangements or instruments for measuring magnetic variables involving magnetic resonance
    • G01R33/44Arrangements or instruments for measuring magnetic variables involving magnetic resonance using nuclear magnetic resonance [NMR]
    • G01R33/46NMR spectroscopy
    • G01R33/4633Sequences for multi-dimensional NMR

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Signal Processing (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente describe un procedimiento para el análisis por resonancia magnética nuclear de residuos en general y de heparinas y heparinas de bajo peso molecular y sus derivados en particular, que permite su identificación así como la cuantificación relativa de sus señales características por ¹H-RMN y ¹H-¹³C HSQC.
ARP170102020A 2016-07-19 2017-07-19 Procedimiento de análisis de glicosaminoglicanos, heparinas y sus derivados por resonancia magnética nuclear AR109099A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16382350.3A EP3273239A1 (en) 2016-07-19 2016-07-19 Procedure of analysis of glycosaminoglycans, heparins and their derivatives by nuclear magnetic resonance

Publications (1)

Publication Number Publication Date
AR109099A1 true AR109099A1 (es) 2018-10-31

Family

ID=56682072

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102020A AR109099A1 (es) 2016-07-19 2017-07-19 Procedimiento de análisis de glicosaminoglicanos, heparinas y sus derivados por resonancia magnética nuclear

Country Status (27)

Country Link
US (2) US10705037B2 (es)
EP (2) EP3273239A1 (es)
JP (1) JP7035007B2 (es)
CN (1) CN109477829B (es)
AR (1) AR109099A1 (es)
AU (1) AU2017299186C1 (es)
BR (1) BR112019000437A2 (es)
CA (1) CA3029924A1 (es)
CL (1) CL2019000038A1 (es)
CO (1) CO2019000087A2 (es)
CR (1) CR20190016A (es)
CY (1) CY1124817T1 (es)
DK (1) DK3452827T3 (es)
DO (1) DOP2019000003A (es)
EA (1) EA037102B1 (es)
ES (1) ES2894898T3 (es)
HR (1) HRP20211649T1 (es)
HU (1) HUE056604T2 (es)
LT (1) LT3452827T (es)
MA (1) MA44876A (es)
PL (1) PL3452827T3 (es)
PT (1) PT3452827T (es)
SI (1) SI3452827T1 (es)
UA (1) UA124466C2 (es)
UY (1) UY37337A (es)
WO (1) WO2018015463A1 (es)
ZA (1) ZA201900143B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102018203434B4 (de) * 2018-03-07 2019-12-05 Bernd Willi Karl-Heinz Diehl Verfahren zur heteronuklearen quantitativen Bestimmung mittels NMR-Spektroskopie, Referenzsubstanzen hierfür und Verfahren zur Bestimmung des Deuterierungsgrades einer deuterierten Verbindung
CN112816566A (zh) * 2019-11-17 2021-05-18 烟台东诚药业集团股份有限公司 一种那屈肝素钙末端结构确认方法
CN111337529B (zh) * 2020-03-12 2023-06-16 青岛科技大学 一种降低粘度、使水峰偏移的多糖样品制备和测试方法
JP7377937B2 (ja) 2021-10-20 2023-11-10 シオノギヘルスケア株式会社 オリゴ糖の還元末端糖の定量的分析方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ519984A (en) 2000-01-07 2004-03-26 Transform Pharmaceuticals Inc High-throughput formation, identification, and analysis of diverse solid-forms
JP4657726B2 (ja) 2002-05-20 2011-03-23 マサチューセッツ インスティテュート オブ テクノロジー Nmrを使用する配列決定のための新規方法
JP2004339083A (ja) 2003-05-13 2004-12-02 Bioserentack Co Ltd ムコ多糖類製剤
JP2005337958A (ja) 2004-05-28 2005-12-08 Kao Corp 水溶性の糖骨格を有する化合物の分析法
JP2005345193A (ja) 2004-06-01 2005-12-15 Shiseido Co Ltd 核磁気共鳴法及び/又は核磁気共鳴による拡散係数測定法を用いた定量方法
JP2006291028A (ja) 2005-04-11 2006-10-26 Q P Corp 低分子ヘパリンまたはその塩、ならびにその製造方法
US7968082B1 (en) * 2007-01-26 2011-06-28 Momenta Pharmaceuticals, Inc. Evaluating mixtures of low molecular weight heparins by NMR
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
EP2213282A1 (en) 2009-01-30 2010-08-04 Laboratorios Farmaceuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
ES2340902B1 (es) 2008-07-01 2011-05-03 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con glicosaminoglicanos y su uso en tratamiento de ulceras cronicas.
ES2336297B1 (es) 2008-10-08 2011-01-24 Laboratorios Farmaceuticos Rovi, S.A. Procedimiento de sintesis de pentasacaridos desprotegidos a partir deun pentasacarido precursos protegido.
JP5372696B2 (ja) 2009-10-20 2013-12-18 杏林製薬株式会社 ジメチルアミノエチルメタクリレート含有共重合体の定量法
EP3011043B1 (en) 2013-06-17 2022-05-11 The University of North Carolina At Chapel Hill Reversible heparin molecules

Also Published As

Publication number Publication date
EP3452827A1 (en) 2019-03-13
HRP20211649T1 (hr) 2022-02-04
EA037102B1 (ru) 2021-02-05
US10705037B2 (en) 2020-07-07
PT3452827T (pt) 2021-11-10
PL3452827T3 (pl) 2022-02-14
EA201990005A1 (ru) 2019-06-28
CO2019000087A2 (es) 2019-04-30
BR112019000437A2 (pt) 2019-04-30
US20190154601A1 (en) 2019-05-23
WO2018015463A1 (en) 2018-01-25
AU2017299186C1 (en) 2023-07-06
AU2017299186A1 (en) 2019-01-24
HUE056604T2 (hu) 2022-02-28
UY37337A (es) 2018-01-31
US10809212B2 (en) 2020-10-20
AU2017299186B2 (en) 2023-04-13
CA3029924A1 (en) 2018-01-25
SI3452827T1 (sl) 2022-01-31
JP2019525166A (ja) 2019-09-05
EP3273239A1 (en) 2018-01-24
CY1124817T1 (el) 2022-11-25
CL2019000038A1 (es) 2019-05-10
CN109477829A (zh) 2019-03-15
LT3452827T (lt) 2021-11-25
WO2018015463A9 (en) 2018-05-11
MA44876A (fr) 2021-04-21
US20200271601A1 (en) 2020-08-27
EP3452827B1 (en) 2021-08-25
CR20190016A (es) 2019-05-17
DK3452827T3 (da) 2021-10-11
ES2894898T3 (es) 2022-02-16
DOP2019000003A (es) 2019-06-30
UA124466C2 (uk) 2021-09-22
ZA201900143B (en) 2019-09-25
CN109477829B (zh) 2022-06-21
JP7035007B2 (ja) 2022-03-14

Similar Documents

Publication Publication Date Title
DOP2019000003A (es) Procedimiento de análisis de glicosaminoglicanos, heparinas y sus derivados por resonancia magnética nuclear
IL268480B (en) Inspection of photomasks by comparing two photomasks
BR112016018314A2 (pt) formação de imagem de alto desempenho e altamente multiplexada com sondas programáveis de ácido nucleico
EA201992183A2 (ru) Синтез полициклических карбамоилпиридоновых соединений
SG11201701822RA (en) Data-driven testing framework
BR112018008960A2 (pt) estrutura de relatório de formação de feixe
BR112015008132A2 (pt) sistema de eletromagnético de calibragem
CO2017005773A2 (es) Composiciones, dispositivos, y métodos de pruebas de sensibilidad del ibs
DK3094959T3 (da) Pladetestapparat
BR112017002662A2 (pt) processo para preparar furfural e/ou derivados de furfural.
DE112018006172A5 (de) Armlehne für einen Innenraum eines Fahrzeugs
MX346698B (es) Metodo y dispositivo de agrupamiento.
BR112017006419A2 (pt) medições cinéticas de tau
DE112017000925A5 (de) Halterung für ein Instrument
BR112017005430A2 (pt) um polímero orgânico curável que compreende pelo menos uma unidade de acilureia, sua preparação e uso.
EP2971495A4 (en) TANGENTIAL FRONT ANTENNA FOR A BORROW MEASUREMENT THROUGH MAGNETIC CORE RESONANCE
BR112017000179A2 (pt) análise de peças de deslocamento para seleção de linhas candidatas para pesquisas sísmicas.
IN2014MU00212A (es)
HUE051975T2 (hu) Eljárás NMR mérés elvégzésére, szonda elrendezés NMR spektrométerhez, és NMR spektrométer elrendezés
BR112018067563A8 (pt) sistemas e métodos para a produção de hipericina sintética.
FI20145810A (fi) Näytteen toksisuuden testaus
BR112018007282A2 (pt) métodos para síntese total de resolvina e1
BR112017009605A2 (pt) método para o diagnóstico da doença de niemann-pick usando um biomarcador
PL432544A1 (pl) Sposób pomiaru profilu uwalniania substancji organicznych i farmaceutycznych kokryształów z porów nanokrzemionki w PBS
PT3590103T (pt) Verificação magnética de documentos de valor